Publication
Title
Mast cell–targeting therapies in mast cell activation syndromes
Author
Abstract
Purpose of Review Provide an overview of the expanding landscape of mast cell (MC)–targeting treatments in mast cell activation syndromes (MCAS). Recent Findings Tyrosine-kinase inhibitors (TKIs) targeting wild-type and mutated KIT can efficiently induce MC depletion. Avapritinib and midostaurin can also temper IgE-mediated degranulation. Avapritinib has been recently approved by the FDA for the treatment of indolent systemic mastocytosis (ISM). Targeting activation pathways and inhibitory receptors is a promising therapeutic frontier. Recently, the anti Siglec-8 antibody lirentelimab showed promising results in ISM. Summary MCAS is a heterogeneous disorder demanding a personalized therapeutic approach and, especially when presenting as anaphylaxis, has not been formally captured as outcome in prospective clinical trials with TKI. Long-term safety of TKI needs to be addressed. New drugs under investigation in diseases in which non-neoplastic MCs play a pivotal role can provide important inputs to identify new efficient and safe treatments for MCAS.
Language
English
Source (journal)
Current allergy and asthma reports. - Philadelphia, Pa, 2001, currens
Current Allergy and Asthma Reports
Publication
Philadelphia, Pa : 2024
ISSN
1529-7322
DOI
10.1007/S11882-023-01123-9
Volume/pages
(2024) , p. 1-9
ISI
001141904500002
Pubmed ID
38217824
Full text (Publisher's DOI)
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
Project info
Can behaviour analysis of individual mast cells and basophils lift the veil of anaphylaxis in mastocytosis?
Role of inhibitory receptors in piecemeal and anaphylactic degranulation of basophils and mast cells.
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identifier
Creation 17.01.2024
Last edited 09.02.2024
To cite this reference